Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic ...

The corporation’s R&D efforts produced several noteworthy obesity treatment readouts, such as amycretin, semaglutide 7.2 milligrams, and CagriSema. At constant exchange rates, Novo Nordisk A/S ...

In January, the company reported that patients receiving the highest dose of amycretin experienced a 22% weight loss compared with a gain in body weight of approximately 2% in those treated with ...

Eli Lilly stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds.

the firm’s amycretin program (that could enter phase 3 this year) looks very promising, and Novo is in-licensing multiple other types of drugs that could be complementary with its internal pipeline.